We are an early stage start-up company having laid the foundation for the development of a class of neuroprotective small molecules with an entirely new pharmacological mode of action. FMP neuroprotectiva are expected to be broadly applicable in the treatment of currently untreatable human neurological conditions. These include vascular brain damage and dementia, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Huntington’s disease (HD), retina degeneration, and brain damage caused by virus or parasite infections.